rationale for switching polycythemia therapy
Published 5 years ago • 28 plays • Length 3:32Download video MP4
Download video MP3
Similar videos
-
1:41
switching therapy in polycythemia vera
-
6:15
initial treatment for polycythemia vera
-
4:26
controlling hematocrit in polycythemia vera
-
1:56
rationale for verify: rusfertide added to ongoing therapy in patients with polycythemia vera
-
4:26
polycythemia vera: switching therapy
-
5:43
moving beyond hydroxyurea for polycythemia vera
-
3:38
future directions for polycythemia vera treatment
-
2:16
determining when to switch from hydroxyurea to interferon-based therapy in patients with pv
-
18:19
biomarker and surrogate targets for successful therapy in polycythemia vera (pv)
-
2:12
initiating cytoreductive therapy in polycythemia vera
-
4:52
treating pv with jak inhibition now and in the future
-
6:07
available treatment options for patients with pv
-
3:37
initiating ruxolitinib for polycythemia vera
-
4:16
testing for polycythemia vera
-
2:07
rationale for jak inhibition in pv
-
3:30
polycythemia vera: treatment goals & risk stratification
-
2:16
the future of polycythemia vera treatment
-
5:36
case 2: ruxolitinib treatment for polycythemia vera
-
5:10
monitoring pv: when to initiate a change in therapy?